ANTI-AGEING 47
120.0 100.0 80.0 60.0 40.0 20.0 0.0
* * * * *
120.0 100.0 80.0 60.0 40.0 20.0 0.0
* *
*
*
Treatment
Figure 4: Results of Caspase-1 expression from treatments of StrataPhix™ POLY on UVB-inflammasome-activated NHEKs. Asterisks indicate statistical significance (p≤0.05).
120.0 100.0 80.0 60.0 40.0 20.0 0.0
Treatment
Figure 5: Results of Caspase-1 expression from treatments of StrataPhix™ AOS on UVB-inflammasome-activated NHEKs. Asterisks indicate statistical significance (p≤0.05).
* * * *
120.0 100.0 80.0 60.0 40.0 20.0 0.0
* *
*
Treatment
Figure 6: Results of Caspase-1 expression from treatments of StrataPhix™ AWS on UVB-inflammasome-activated NHEKs. Asterisks indicate statistical significance (p≤0.05).
Clinical examination of the polysaccharide blend on skin barrier recovery from tape stripping
A blinded clinical study was undertaken to examine in vivo the effects of the polysaccharide blend noted above on ten (10) volunteers (7 male, 3 Female, Ages 25- 60) to examine skin barrier recovery after a tape stripping disruption.10
The volunteers,
who all signed informed consent, were recruited to examine the impact of application of a formulation containing the water-soluble polysaccharide blend at 3%. Each volunteer was tape stripped at two locations on the inner volar forearm to disrupt the skin’s barrier and a third location served as an undisrupted control site. Tape stripping was done so that each site had an initial TEWL measurement that was at least 2X the TEWL value of a non-tape-stripped control site. In most cases, approximately 15-20 tape strips (3M Duct Tape) produced the desired TEWL values required to initiate treatments. Product application commenced 1 hour after the tape stripping and initial measurements and photographs and continued for 60 hours with treatments 2X/day with two formulations: 1) a placebo
April 2020
Treatment
Figure 7: Results of Caspase-1 expression from treatments of StrataPhix™ POLY on ATP-inflammasome-activated NHEKs. Asterisks indicate statistical significance (p≤0.05).
cream and 2) the same cream containing 3% of the polysaccharide blend. Trans- Epidermal Water Loss (TEWL) was measured using a DermaLab TEWL-meter [Cortex Technology, Hadsund, Denmark]. Measurements were made under controlled air-conditioned conditions at 23°C and approximately 30 RH. The entire protocol can be seen in Figure 8. To examine the impact of the
treatments, the difference in the overall average TEWL measurements at T0 (initial measurement) and T5 (final measurement) were examined, Fig 9. Examining the change gives an indication as to how effectively the active treatment compared against the placebo treatment. As can be seen, the overall rate of barrier recovery for the active-treated site was significantly higher than the placebo-treated site by approximately 6% (Paired T-Test, p≤0.05) and both sites improved significantly compared to the untreated site. In addition, the Erythemal Index of the skin was examined using a DermaLab Chromometer [Cortex Technologies, Hadsund, Denmark]. The change in redness from T0 to T5 indicates that the active-treated site improves
more quickly than the placebo site by 36%, indicating the active treatment appears to be also helping to reduce skin redness over the treatment time frame (Fig 10).
Photographs of each individual show
differences between the control site and the active and placebo sites and a representative example of one test subject’s inner volar forearm taken in natural sunlight to enhance the barrier disruption appearance at T0 and T5 is shown in Figure 11. The instrumental and photographic data indicate that the treatment containing the 3% polysaccharide blend functioned superiorly to the placebo treatment at accelerating the repair of the skin’s disrupted barrier. Additional studies are being planned to examine inflammation resulting from UV exposure to examine the benefits of the antioxidant blends.
Clinical examination of the polysaccharide blend on extended skin hydration There is a well-established link between wound healing and the moisture content of the skin. The most common example of this is how much more quickly wounds inside of the mouth heal compared to wounds outside
PERSONAL CARE EUROPE
Caspase-1 Activation (Percent of Untreated)
Caspase-1 Activation (Percent of Untreated)
Caspase-1 Activation (Percent of Untreated)
Caspase-1 Activation (Percent of Untreated)
Non-Stimulated Untreated 100 µM MCC950 Non-Stimulated Untreated 100 µM MCC950
0.005% Water-Soluble Antioxidant Blends
0.01% Water-Soluble Antioxidant Blends
0.05% Water-Soluble Antioxidant Blends
0.1% Water-Soluble Antioxidant Blends
0.1% Polysaccharide Blend 0.5% Polysaccharide Blend 1% Polysaccharide Blend 2% Polysaccharide Blend 3% Polysaccharide Blend
Non-Stimulated Untreated
0.1% DMSO 100 µM MCC950 0.000001% Oil-Soluble Blend
Non-Stimulated Untreated
100 µM MCC950
0.1% Polysaccharide Blend 0.5% Polysaccharide Blend 1% Polysaccharide Blend 2% Polysaccharide Blend 3% Polysaccharide Blend
0.00001% Oil-Soluble Blend 0.0001% Oil-Soluble Blend 0.001% Oil-Soluble Blend
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92 |
Page 93 |
Page 94 |
Page 95 |
Page 96 |
Page 97 |
Page 98 |
Page 99 |
Page 100 |
Page 101 |
Page 102 |
Page 103 |
Page 104 |
Page 105 |
Page 106 |
Page 107 |
Page 108 |
Page 109 |
Page 110 |
Page 111 |
Page 112 |
Page 113 |
Page 114 |
Page 115 |
Page 116 |
Page 117 |
Page 118 |
Page 119 |
Page 120 |
Page 121 |
Page 122 |
Page 123 |
Page 124 |
Page 125 |
Page 126 |
Page 127 |
Page 128 |
Page 129 |
Page 130 |
Page 131 |
Page 132 |
Page 133 |
Page 134 |
Page 135 |
Page 136 |
Page 137 |
Page 138 |
Page 139 |
Page 140 |
Page 141 |
Page 142 |
Page 143 |
Page 144 |
Page 145 |
Page 146 |
Page 147 |
Page 148 |
Page 149 |
Page 150 |
Page 151 |
Page 152 |
Page 153 |
Page 154 |
Page 155 |
Page 156 |
Page 157 |
Page 158 |
Page 159 |
Page 160 |
Page 161 |
Page 162 |
Page 163 |
Page 164 |
Page 165 |
Page 166 |
Page 167 |
Page 168 |
Page 169 |
Page 170 |
Page 171 |
Page 172 |
Page 173 |
Page 174 |
Page 175 |
Page 176 |
Page 177 |
Page 178 |
Page 179 |
Page 180 |
Page 181 |
Page 182 |
Page 183 |
Page 184 |
Page 185 |
Page 186 |
Page 187 |
Page 188 |
Page 189 |
Page 190 |
Page 191 |
Page 192 |
Page 193 |
Page 194 |
Page 195 |
Page 196
